DAY 2 / ‏‏‎ ‎

08:00 AM - 09:00 AM
09:00 AM - 09:00 AM
Research & Discovery

Track Chair

Brian S. Martin, Head of AI R&D; Information Research, AbbVie
Clinical Development

Track Chair


Track Chair

09:00 AM - 09:25 AM
Research & Discovery View Session

Using AI to Hit the Right Targets

Use Case: Discovery of splicing-based therapeutics with the SpliceCore platform

Martin Akerman, Co-founder and CTO, Envisagenics
Clinical Development

Digital Therapeutics


AI and Genomics Efficacy Across the Pipeline

George Church, Ph.D, Professor of Genetics, Blavatnik Institute, Harvard Medical School; Director of HMS NHGRI-Center of Excellence in Genomic Science; Director of the Personal Genome Project, Broad Institute & Wyss Harvard Inst. of Biologically Inspired Engineering
09:30 AM - 09:55 AM
Clinical Development


Genomics View Session

Leveraging AI & Genomics in Discovery of New Drugs/Discovery

Use Case: Setting a new record on the pathway from Patient to Diagnostic to Targeted Treatment in Rare Disease

This use case will delve into a neo-natal intensive care unit case at Rady’s Children hospital wherein a collaborative effort leveraging AI to integrate genomic and clinical record information established a new world record for fastest genomic/AI-based diagnosis. Underlying technologies/capabilities to enable the record – and current next frontiers of research will be discussed.

John Reynders, Vice President, Data Science, Genomics, and Bioinformatics, Alexion Pharmaceuticals, Inc.
10:00 AM - 10:25 AM
10:25 AM - 10:55 AM
10:55 AM - 11:20 AM
Research & Discovery Clinical Development View Session

Regulatory & Policy

Use Case: Application of AI to Predict a New Class of Novel Synthetic Lethal Targets Leading to More Effective and Safer Oncology Therapeutic Programs

  • AI research and insights using the ExpansiveAI platform
  • Scalable mining of data connections, testing masses of hypotheses, cognitive computing and ML to discover novel targets
  • Bioinformatic filtering, in-silico validation, prioritizing targets aimed at vulnerable cancer cells harboring a specific gene change
  • Launching new effective and safer therapeutic programs
Spyro Mousses, Ph.D, Chief Executive Officer, Systems Oncology
11:25 AM - 11:50 AM
Research & Discovery Clinical Development

Policy Decisions that Can Help or Hinder the Use of AI Tools

11:55 AM - 12:55 PM
Plenary View Session

Open Discussion Session Panel

Several industry pioneers will lead an audience-wide discussion on a topic that is impacting the industry and patients now. This is your unique opportunity to gain an understanding of how industry peers are innovating This is also a great opportunity to expand your network and possibly find your next partner.

12:55 PM - 1:00 PM

Closing Remarks

Harry Glorikian, General Partner, New Ventures Funds
Author: MoneyBall Medicine: Thriving in the New Data-Driven Healthcare Market
/* */